Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, James SJ: Homocysteine metabolism in children with Down syndrome: in vitro modulation
Sanin Syed: Rochesters Leading GLP-1 Weight Loss Specialist When it comes to managing complex medical treatments like GLP-1 receptor agonist therapy, the expertise and credentials of your physician matter enormously
People taking retatrutide, a drug being developed by Eli Lilly, lost an average of more than 70 pounds, or 28.3% of their bodyweight, over the course of 80 weeks, according to the company's preliminary report of clinical trial results
Common side effects include mild nausea, reduced appetite, and occasional gastrointestinal changes during initial weeks as your body adjusts
Drug-Drug Interactions Anticoagulants or Antiplatelets : Concurrent use with blood-thinning medications like warfarin or aspirin may increase the risk of bleeding
NICE guidance recommends reviewing GLP-1 therapy at 6 months, continuing only if HbA1c has reduced by at least 11 mmol/mol and weight has decreased by at least 3% of initial body weight for diabetes treatment
